Department of Pathology and Laboratory Medicine, University of California at Davis Medical Center, Sacramento, CA 95831, USA.
Department of Food Science and Technology, Department of Viticulture and Enology, Foods for Health Institute, University of California, Davis, CA 95616, USA.
Exp Biol Med (Maywood). 2014 Nov;239(11):1489-504. doi: 10.1177/1535370214538743. Epub 2014 Jun 20.
Because of increasingly widespread sedentary lifestyles and diets high in fat and sugar, the global diabetes and obesity epidemic continues to grow unabated. A substantial body of evidence has been accumulated which associates diabetes and obesity to dramatically higher risk of cancer development, particularly in the liver and gastrointestinal tract. Additionally, diabetic and obese individuals have been shown to suffer from dysregulation of bile acid (BA) homeostasis and dysbiosis of the intestinal microbiome. Abnormally elevated levels of cytotoxic secondary BAs and a pro-inflammatory shift in gut microbial profile have individually been linked to numerous enterohepatic diseases including cancer. However, recent findings have implicated a detrimental interplay between BA dysregulation and intestinal dysbiosis that promotes carcinogenesis along the gut-liver axis. This review seeks to examine the currently investigated interactions between the regulation of BA metabolism and activity of the intestinal microbiota and how these interactions can drive cancer formation in the context of diabesity. The precarcinogenic effects of BA dysregulation and gut dysbiosis including excessive inflammation, heightened oxidative DNA damage, and increased cell proliferation are discussed. Furthermore, by focusing on the mediatory roles of BA nuclear receptor farnesoid x receptor, ileal transporter apical sodium dependent BA transporter, and G-coupled protein receptor TGR5, this review attempts to connect BA dysregulation, gut dysbiosis, and enterohepatic carcinogenesis at a mechanistic level. A better understanding of the intricate interplay between BA homeostasis and gut microbiome can yield novel avenues to combat the impending rise in diabesity-related cancers.
由于久坐不动的生活方式和高脂肪、高糖的饮食日益普及,全球糖尿病和肥胖症的流行仍在继续加剧。大量证据表明,糖尿病和肥胖症与癌症发展的风险显著增加有关,尤其是在肝脏和胃肠道。此外,糖尿病和肥胖个体的胆汁酸(BA)稳态失调和肠道微生物组的失调也已得到证实。异常升高的细胞毒性次级 BAs 水平和肠道微生物群谱的促炎转变已分别与多种肠肝疾病(包括癌症)有关。然而,最近的研究结果表明,BA 失调和肠道菌群失调之间存在有害的相互作用,可沿着肠道-肝脏轴促进癌症发生。这篇综述旨在探讨目前对 BA 代谢调节和肠道微生物群活性之间相互作用的研究,以及这些相互作用如何在糖尿病肥胖的背景下促进癌症形成。讨论了 BA 失调和肠道菌群失调的致癌前作用,包括过度炎症、氧化 DNA 损伤增加和细胞增殖增加。此外,通过关注 BA 核受体法尼酯 X 受体、回肠转运体顶端钠依赖性 BA 转运体和 G 蛋白偶联受体 TGR5 的介导作用,本综述试图在机制水平上连接 BA 失调、肠道菌群失调和肠肝内癌发生。更好地理解 BA 稳态和肠道微生物组之间复杂的相互作用,可以为应对即将出现的糖尿病肥胖相关癌症提供新的途径。
Exp Biol Med (Maywood). 2014-6-20
Cell Mol Gastroenterol Hepatol. 2020
Biomed Pharmacother. 2021-1
J Cachexia Sarcopenia Muscle. 2021-12
World J Microbiol Biotechnol. 2025-6-25
Eng Microbiol. 2024-12-30
Front Endocrinol (Lausanne). 2025-5-29
Diseases. 2025-4-15
Clin Transl Gastroenterol. 2024-11-1
Cell Mol Gastroenterol Hepatol. 2024
Nature. 2013-12-11
J Gastroenterol Hepatol. 2014-1
World J Gastroenterol. 2013-10-28
Am J Physiol Gastrointest Liver Physiol. 2013-10-3
Scand J Gastroenterol. 2013-11
Pediatr Gastroenterol Hepatol Nutr. 2013-3